Anti-PD-L1 antibodies have been observed to foster lipid peroxide-mediated ferroptosis in proliferating cancer cells, with the efficacy of anti-PD-L1 antibody therapy being compromised by ferroptosis inhibitors (258). Here, CD274 is linked to cancer.